• Biophan Technologies (Rochester, New York), a developer of next-generation medical technology, said that it has filed a U.S. patent application for the use of halloysite nanotubes for controlled release of drugs. The technology uses halloysite nanotubes, which are being commercialized by NaturalNano (Rochester, New York). The nanotubes, which are hollow inorganic nanostructures derived from clay, allow the linear, controlled release of drugs. In addition, the nano-chopping technology being developed allows for achieving precisely defined sizes of nanotubes to ensure the predictable performance and dosing required for a given drug, Biophan said. The technology covered in Biophan's new patent complements NaturalNano's technology for the extraction, separation, and classification of halloysite nanotubes to the high-precision levels needed by the pharmaceutical industry, NaturalNano said.

• BodyMedia (Pittsburgh), a provider of continuous body monitoring systems for clinical and consumer healthcare markets, said it has received another patent on the current and next generations of its wearable body monitoring platform. U.S. patent No. 7,020,508, "Apparatus for Detecting Human Physiological and Contextual Information," covers elements of enabling medical-grade wearable body monitoring for free-living consumer and clinical applications. The broad patent contains more than 220 claims covering numerous embodiments of intelligent wearable monitoring related apparatuses, including proprietary sensors, ergonomic wearability and body attachment features for greater comfort, placement flexibility, and sensing quality.

• Chembio Diagnostics (Medford, New York) said it has developed Dual Path Platform (DPP) technology for rapid diagnostic tests that offers significant advantages over the lateral flow technology used in commercially available rapid diagnostic tests. A presentation on DPP at the International Symposium on Immunobiologicals and Human Health which ends today in Rio de Janeiro, Brazil, found that the independent flow paths for DPP sample and conjugate assays increase the efficiency of antibody binding to the immobilized test antigen, which leads to improved sensitivity in several of the different assays being developed. Chembio has completed feasibility studies on a number of rapid test applications utilizing DPP technology for HIV, tuberculosis and other diseases. These studies confirm the advantages of DPP technology over single-path lateral flow designs, the company said.

• Cybernet Medical (Ann Arbor, Michigan), a developer of telemedicine technology for outpatient care, reported the release of a telemonitoring solution for its web-based electronic patient record system, MedStar. MedStar users can now offer patients who browse the web a fully functional version of the MedStar without in-home patient hardware. MedStar offers full vital signs data acquisition, AI-powered question-and-answer logic that can be delivered via the web or by interactive voice response, and two-way IP phone and video service between the patient and caregiver. The patient only needs a browser-enabled PC, Internet service and a broadband connection for two-way video service. A special version of the MedStar data hub is optionally available to connect physiological measurement devices to the user's PC for automated data upload. The product was released at the American Telemedicine Association 2006 trade show in San Diego.

• Eklin Medical Systems (Santa Clara, California), a provider of veterinary PACS, Practice Information Management (PIMS) software and digital radiography products, said it has added two new options to its RapidView diagnostic workstation product line. The new additions include the RapidView 2GSi, for detailed radiographic studies, and the RapidView SD-1C, designed especially for client education. The Eklin RapidStudy DR system provides the veterinarian with a radiographic image that can be viewed immediately on a high-resolution monitor without need for film developing. The Eklin DR system also offers sophisticated image processing tools. Eklin offers either a 9"x11" sensor panel or a full- size 14"x17" sensor panel. Images can be stored and archived for future evaluation using the Eklin PACS, which is based on DICOM standards. In addition, medical records, lab results, billing, financial statements and other pertinent patient or practice information are available with Eklin's VIA PIMS.

• Guardian Healthcare Systems (Herndon, Virginia), a division of Guardian Technologies International, reported the release of FlowPoint 6.1, an integrated, web-based radiology information system (RIS) and PACS that enables healthcare enterprises to combine patient medical data and radiology images into one digital record. FlowPoint 6.1 includes an optional module for report dictation using the Dragon NaturallySpeaking SDK software developers toolkit from Nuance Communications (Silver Spring, Maryland). FlowPoint 6.1 also includes digital voice-recording capability integrated with the voice-recognition system. FlowPoint 6.1 includes additional updates and enhancements, including a larger label printing library of templates; extended international language vocabularies; an updated set of Crystal Reports, which address referring physician exam volumes and modality analysis reporting; an enhanced scheduling and calendar module that displays more patient exam information, enabling quicker access to important information; the ability to share information with an unlimited number of referring physicians; and enhanced search tools.

• Nymox Pharmaceutical (Hasbrouck Heights, New Jersey) said that positive results from clinical studies of the company's AlzheimAlert test will be presented at the annual meeting of the American Psychiatric Association in Toronto later this month. The AlzheimAlert test is a urine-based diagnostic aid for Alzheimer's disease (AD). It is the only proven accurate non-invasive AD test technology available. The test has the CE mark in Europe, and is CLIA certified as a laboratory test service which is available in the U.S.

• OcuSense (San Diego), a developer of doctor's office-based tests for eye care, has received notice from the U.S. Patent and Trademark Office of issuance of a core patent, No. 7,017,394. "Tear Film Osmometry" claims a lab-on-a-chip approach to measure tear osmolarity for the diagnosis and management of Dry Eye Syndrome. The patent covers the use of microelectronic sensors that can reliably detect osmolarity in small fluid volumes. OcuSense embeds its sensors into proprietary, microfluidic lab cards that then rapidly process the tear samples without the risk of evaporation. The entire test is expected to take only two minutes to perform, and helps the eye care practitioner more accurately prescribe appropriate treatment or ensure a better contact lens fit.

• Planar Systems (Beaverton, Oregon), a manufacturer of flat-panel display systems, said it has selected ATI Technologies (Markham, Ontario), a manufacturer of 3-D graphics, PC platform technologies and digital media silicon solutions, to provide advanced graphics processing technology for its medical imaging products. Planar's Dome AX4 is built with the new ATI FireGL V3400, a commercially-available workstation graphics board created to accelerate the speed at which users can load, review, report and communicate patient cases with colleagues. With the integration of the ATI FireGL V3400, Planar's Dome EX series allows users to experience enhanced visualization of various color modalities, 2-D color imaging, image fusion and 3-D imaging with faster delivery and image processing. ATI FireGL V3400 graphics controller boards will be offered with Planar's Dome series E2, E2c, E3, E3c and E4c, as well as the P1 Bundle and P2 Bundle.